Abstract: Provided herein are methods and compositions for modulating gene expression in insects by administering a composition comprising an RNA effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction and/or viability. Also provided herein are methods for treating or preventing disease in an insect caused by a pathogen or by external factors (e.g., pollution, environment, stress, weather, etc.).

Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.

Abstract: Compounds, compositions and methods are provided for modulating the RNAi pathway. The compositions comprise oligonucleotides, targeted to nucleic acid molecules encoding EIF2C2. Methods of using these compounds for modulation of RNA interference as well as EIF2C2 expression and for diagnosis and treatment of disease associated with expression of EIF2C2 are provided. Also provided are compounds, compositions and methods for modulating the expression of DDX36. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DDX36. Methods of using these compounds for modulation of DDX36 expression and for diagnosis and treatment of diseases and conditions associated with expression of DDX36 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of hypoxia-inducible factor 1 alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding hypoxia-inducible factor 1 alpha. Methods of using these compounds for modulation of hypoxia-inducible factor 1 alpha expression and for diagnosis and treatment of disease associated with expression of hypoxia-inducible factor 1 alpha are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of PAI-1 mRNA-binding protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding PAI-1 mRNA-binding protein. Methods of using these compounds for modulation of PAI-1 mRNA-binding protein expression and for diagnosis and treatment of disease associated with expression of PAI-1 mRNA-binding protein are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1&agr; and/or HIF2&agr;. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1&agr; and HIF2&agr;. Methods of using these compounds for modulation of HIF1&agr; and/or HIF2&agr; expression and for diagnosis and treatment of disease associated with expression of HIF1&agr; and/or HIF2&agr; are provided.

Abstract: The present invention provides modified oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds are each prepared having a 5′-phosphate precursor which can be modulated to provide a 5′-phosphate group under selected conditions. In another embodiment of the invention the 5′-phosphate precursor is labile inside a target cell thereby providing an oligomeric compounds having a 5′-phosphate intercellularly.

Abstract: Compounds, compositions and methods are provided for modulating the expression of sentrin-2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding sentrin-2. Methods of using these compounds for modulation of sentrin-2 expression and for diagnosis and treatment of disease associated with expression of sentrin-2 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Glucose transporter-4. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Glucose transporter-4. Methods of using these compounds for modulation of Glucose transporter-4 expression and for diagnosis and treatment of disease associated with expression of Glucose transporter-4 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of hypoxia-inducible factor 1 alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding hypoxia-inducible factor 1 alpha. Methods of using these compounds for modulation of hypoxia-inducible factor 1 alpha expression and for diagnosis and treatment of disease associated with expression of hypoxia-inducible factor 1 alpha are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of cytokine-inducible kinase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding cytokine-inducible kinase. Methods of using these compounds for modulation of cytokine-inducible kinase expression and for diagnosis and treatment of disease associated with expression of cytokine-inducible kinase are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK3. Methods of using these compounds for modulation of MEKK3 expression and for treatment of diseases associated with expression of MEKK3 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ADAM12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ADAM12. Methods of using these compounds for modulation of ADAM12 expression and for treatment of diseases associated with expression of ADAM12 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MARK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MARK3. Methods of using these compounds for modulation of MARK3 expression and for treatment of diseases associated with expression of MARK3 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Rb2/p130. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Rb2/p130. Methods of using these compounds for modulation of Rb2/p130 expression and for treatment of diseases associated with expression of Rb2/p130 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK2. Methods of using these compounds for modulation of MEKK2 expression and for treatment of diseases associated with expression of MEKK2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL. Methods of using these compounds for modulation of RECQL expression and for treatment of diseases associated with expression of RECQL are provided.